A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

被引：0

作者：

Fowler, Nathan ^{[1
]}

McLaughlin, Peter ^{[1
]}

Hagemeister, Fredrick B. ^{[1
]}

Kwak, Larry ^{[1
]}

Fanale, Michelle ^{[1
]}

Neelapu, Sattva ^{[1
]}

Fayad, Luis ^{[1
]}

Pro, Barbara ^{[1
]}

Sergent, Crystal ^{[1
]}

White, Shana R. S. ^{[1
]}

Samaniego, Felipe ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：683 / 683

页数：1

共 50 条

[1] Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma [J].

Fowler, N. H. ;

McLaughlin, P. ;

Kwak, L. ;

Hagemeister, F. ;

Fanale, M. ;

Fayad, L. ;

Pro, B. ;

Samaniego, F. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

[2] Complete response rates with lenalidonide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. [J].

Fowler, N. H. ;

McLaughlin, P. ;

Hagemeister, F. B. ;

Kwak, L. W. ;

Fanaie, M. A. ;

Neelapu, S. S. ;

Fayad, L. ;

Orlowski, R. Z. ;

Wang, M. ;

Samaniego, F. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[3] Chemokine upregulation in response to rituximab in B-cell non-Hodgkin's lymphoma. [J].

Ansell, SM ;

Tschumper, RC ;

Witzig, TE ;

Kurtin, PJ ;

Jelinek, DF .

BLOOD, 1999, 94 (10) :86A-86A

[4] Rituximab therapy for indolent non-Hodgkin's lymphoma [J].

Hagenbeek, A ;

Czuczman, MS ;

Ghielmini, M ;

Herold, M ;

Kimby, E ;

Solal-Céligny, P ;

Unterhalt, M .

ANTI-CANCER DRUGS, 2002, 13 :S11-S17

[5] A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma [J].

Witzig, T. E. ;

Nowakowski, G. S. ;

Habermann, T. M. ;

Goy, A. ;

Hernandez-Ilizaliturri, F. J. ;

Chiappella, A. ;

Vitolo, U. ;

Fowler, N. ;

Czuczman, M. S. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1667-1677

[6] Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma [J].

Murali Kesavan ;

Toby A. Eyre ;

Graham P. Collins .

Current Hematologic Malignancy Reports, 2019, 14 :207-218

[7] Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma [J].

Kesavan, Murali ;

Eyre, Toby A. ;

Collins, Graham P. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (04) :207-218

[8] Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma [J].

Tobinai, Kensei ;

Ishizawa, Ken-ichi ;

Ogura, Michinori ;

Itoh, Kuniaki ;

Morishima, Yasuo ;

Ando, Kiyoshi ;

Taniwaki, Masafumi ;

Watanabe, Takashi ;

Yamamoto, Joji ;

Uchida, Toshiki ;

Nakata, Masanobu ;

Terauchi, Takashi ;

Nawano, Shigeru ;

Matsusako, Masaki ;

Hayashi, Masaki ;

Hotta, Tomomitsu .

CANCER SCIENCE, 2009, 100 (10) :1951-1956

[9] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma. [J].

Van der Jagt, Richard H. ;

Cohen, Philip ;

Cheson, Bruce D. ;

Tulpule, Anil ;

Herst, Jordan A. ;

Lemieux, Bernard ;

Schwartzberg, Lee S. ;

Robinson, Katherine Sue ;

Oliver, Jennifer W. ;

Williams, Michael E. .

BLOOD, 2006, 108 (11) :766A-766A

[10] Combination of plitidepsin and rituximab is effective for treatment of rituximab resistant Non-Hodgkin's B-cell lymphoma [J].

Barboza, Nora ;

Medina, Daniel ;

Budak, Tulin ;

Aracil, Miguel ;

Paz, Me ;

Bertino, Joseph ;

Banerjee, Debabrata .

CANCER RESEARCH, 2009, 69

← 1 2 3 4 5 →